Pfizer’s Braftovi Combo Yields 64.4% Response Rate in Colorectal Cancer Trial
Pfizer reported Phase 3 BREAKWATER trial results showing its Braftovi plus cetuximab and FOLFIRI regimen achieved a 64.4% confirmed objective response rate in BRAF V600E-mutant metastatic colorectal cancer, versus 39.2% for standard-of-care. The regimen received accelerated FDA approval in December 2024, with full approval contingent on verification of clinical benefit.
1. Oncology Growth and Q4 Outlook
Pfizer’s oncology division is projected to deliver low-double-digit revenue growth in Q4, driven primarily by the integration of Seagen’s antibody-drug conjugates. Management highlighted a 22% year-over-year increase in Trodelvy sales and a 15% rise in Xtandi revenue globally. These gains are expected to be partially offset by ongoing price compression in mature markets and intensified competition in lung and breast cancer indications. Investors should watch for detailed unit volume metrics and gross margin trends in the upcoming earnings release to gauge the sustainability of this momentum.
2. Patent Expirations and Balance Sheet Pressure
The company faces significant revenue headwinds through 2030 as key products like Eliquis and Ibrance lose exclusivity. Analysts estimate a combined annual revenue decline of $8 billion at peak loss of exclusivity. To buffer these shortfalls, Pfizer closed its $7 billion acquisition of Medsera, expanding its rare disease portfolio but increasing net debt by approximately 12% to $38 billion. Credit agencies have indicated potential pressure on Pfizer’s BBB+ rating if free cash flow does not rebound above $15 billion annually by 2026.
3. Analyst Consensus and Capital Allocation
Twenty brokerages currently assign an average ‘Hold’ recommendation to Pfizer, with consensus reflecting cautious optimism around near-term earnings stability. One firm advocates a ‘Sell’ stance, while six recommend ‘Buy’ or ‘Strong Buy’ ratings. The average 12-month target implies negligible upside from current levels. On the shareholder return front, Pfizer’s quarterly dividend of $0.43 per share yields 6.8% and carries a payout ratio near 100%, constraining share buybacks until post-patent-cliff cash flow recovery.
4. Obesity Drug Market Potential
CEO Albert Bourla likened the anticipated consumer rollout of Pfizer’s oral obesity candidate to the historic uptake of Viagra, forecasting peak annual sales exceeding $5 billion. The company plans a direct-to-consumer strategy supported by digital engagement tools and primary care partnerships. Phase 3 data readouts are slated for mid-2026, with U.S. regulatory filings expected in late 2026. Success in this franchise could offset declines in legacy therapies and bolster long-term growth prospects.